The Law Offices of Vincent Wong
SHAREHOLDER ALERT: IFF SRPT TXT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Wednesday, September 11, 2019 10:00 PM
NEW YORK, NY / ACCESSWIRE / September 11, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
International Flavors & Fragrances Inc. (NYSE: IFF)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/international-flavors-fragrances-inc-loss-submission-form?prid=3453&wire=1
Lead Plaintiff Deadline: October 11, 2019
Class Period: May 7, 2018 to August 5, 2019
Allegations against IFF include that: (1) that Frutarom Industries Ltd. ("Frutarom"), which the Company acquired in 2018, had bribed customers in Russia and Ukraine; (2) that senior management at Frutarom were aware of such improper payments; (3) that, as a result, Frutarom’s financial results were materially overstated; (4) that, as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) that the Company had not completed adequate due diligence before acquiring Frutarom; (6) that, as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sarepta-therapeutics-inc-loss-submission-form?prid=3453&wire=1
Lead Plaintiff Deadline: October 29, 2019
Class Period: September 6, 2017 to August 19, 2019
Allegations against SRPT include that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.
Textron Inc. (NYSE: TXT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/textron-inc-loss-submission-form?prid=3453&wire=1
Lead Plaintiff Deadline: October 21, 2019
Class Period: January 31, 2018 to October 17, 2018
Allegations against TXT include that: (1) end market sales of Arctic Cat products were slowing, resulting in a massive glut of old Arctic Cat inventory on dealers’ floors; (2) in order to clear out this old inventory, the Company provided significant price discounts, which negatively impacted Textron’s earnings; and (3) as a result, Textron’s positive statements about Arctic Cat’s business, operations, and prospects lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong